RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--July 6, 2006--Talecris Biotherapeutics announced today that the Food and Drug Administration (FDA) has approved new product labeling language for Thrombate III® (Antithrombin III (Human)), the only FDA-approved therapy for hereditary antithrombin III (AT-III) deficiency. The new labeling, currently under revision to incorporate the FDA-approved language, provides reasonable assurance for patients and healthcare providers that the manufacturing process for Thrombate III® removes the risk of low levels of infectivity from pathogenic prions. The new labeling also reaffirms the proven safety profile of Thrombate III®, derived from 14 years of clinical experience.
